Helping Cure Opioid Addiction with the Billion-Dollar Ibogaine Market

Psychedelics are the real deal. They can help people in need, change the world, and make a lot of money, all at the same time.

The severity of the opioid crisis has been well documented and needs a solution: One that is able to reduce the both the strain on thousands impacted by the crisis and the economic drain to the tune of billions of dollars.  

One of the companies leading the charge is Universal Ibogaine. The Company’s Chairman is Shayne Nyquvest, formerly the Executive VP of Mackie Research Capital and a founding member of the Cannacord Genuity Group, and he recently sat down with Omri Wallach of Stockhouse Media to dive into the exciting market opportunity on-hand.

The highlights include:

• An $8-billion-dollar potential market swing.
• Universal Ibogaine’s 95% effective rate for getting patients through detox.
• The next important steps for the psychedelics market.